Welcome to our dedicated page for Arcturus Therapeutics Holdings news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therapeutics Holdings stock.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), founded in 2013 and based in San Diego, California, is a pioneering RNA medicines company focused on developing novel therapeutics for rare diseases, particularly those with no adequate treatments. Specializing in RNA interference (RNAi) technologies, Arcturus is at the forefront of creating breakthrough treatments aimed at liver and respiratory diseases.
Arcturus operates primarily in the research and development sector, focusing on nucleic acid-based medical applications. Core technologies include its proprietary LUNAR® lipid-mediated delivery and STARR® mRNA Technology (sa-mRNA), enabling a versatile range of RNA therapeutics. Its mRNA drug substance and product manufacturing expertise further position Arcturus as a leader in RNA-based solutions.
Key projects in Arcturus' pipeline include:
- LUNAR-OTC for treating ornithine transcarbamylase deficiency
- LUNAR-CF aimed at cystic fibrosis
- LUNAR-FLU and LUNAR-COV19 for influenza and COVID-19 vaccines respectively
Recently, Arcturus announced a collaborative research endeavor with PassPort Technologies Inc. (PPTI) to explore innovative mRNA formulations and transdermal delivery methods for vaccines and therapeutics. This partnership leverages ARCT’s LUNAR® platform and PPTI’s PassPort® transdermal technology, aiming to enhance the delivery and efficacy of RNA-based treatments.
Further cementing its competitive edge, Arcturus has developed Kostaive®, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine. Arcturus continues its global collaboration with CSL Seqirus for mRNA vaccines and maintains a joint venture in Japan, ARCALIS, to manufacture mRNA vaccines and therapeutics. The company’s extensive patent portfolio, covering over 400 patents across the U.S., Europe, Japan, China, and other countries, underscores its innovative prowess.
Financially, Arcturus maintains a solid growth trajectory, driven by its robust research initiatives and strategic alliances. For more detailed information, visit their official website at www.ArcturusRx.com, and connect via Twitter and LinkedIn.
Arcturus Therapeutics Holdings announced significant financial results for Q4 2022, highlighting a revenue surge to $160.3 million, driven by a $200 million payment from CSL collaboration. The company achieved $90 million in development milestones in March 2023, bolstering its cash runway into 2026. ARCT-154 Phase 3 trial for COVID-19 booster is fully enrolled in Japan, with ARCT-810 and ARCT-032 advancing in clinical trials. The company reported a net income of $117.3 million for Q4, compared to a loss the previous year. Cash balance was $391.9 million at year-end, reflecting a robust financial position.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will release its financial results for the fourth quarter and full year ended December 31, 2022, after market close on March 28, 2023. A conference call will follow that day at 4:30 p.m. ET. Additionally, Arcturus will present at the Guggenheim Healthcare Talks: Genomic Medicines & Rare Disease Day on April 3, 2023, at 2:10 p.m. ET. Founded in 2013 and based in San Diego, Arcturus focuses on developing mRNA medicines and vaccines for infectious diseases and rare liver and respiratory diseases. The company employs LUNAR® lipid-mediated delivery and STARR™ mRNA Technology to support its diverse pipeline.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced its participation in two upcoming investor conferences. The SVB Securities Global Biopharma Conference will take place on
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced the approval of its Clinical Trial Application (CTA) for ARCT-032, an inhaled mRNA treatment for cystic fibrosis (CF). This marks the progression into Phase 1 First-in-Human studies in New Zealand. Joseph Payne, CEO, emphasized the potential of ARCT-032 to restore CFTR protein in CF patients, including those without effective treatment options. Preclinical data showcased robust CFTR expression in human bronchial epithelial cells. Cystic fibrosis, a serious genetic disorder, currently lacks effective treatments for many mutation types, making this development particularly significant.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced its participation in the Annual J.P. Morgan Healthcare Conference in San Francisco on January 11, 2023, at 9:00 a.m. Pacific Time. The company, known for its mRNA medicines and vaccines, will discuss its pipeline focused on vaccines for infectious diseases and treatments for rare liver and respiratory diseases. A webcast of the presentation will be available on the company's investor relations website.
Founded in 2013, Arcturus continues to innovate in RNA therapeutics with extensive patent coverage.
Arcturus Therapeutics, a late-stage clinical mRNA medicines company, has appointed John Markels, Ph.D., to its Board of Directors. With over 35 years of industry experience, including as President of Global Vaccines at Merck, Dr. Markels will provide strategic oversight for the company's vaccine franchise and manufacturing processes. This appointment is expected to enhance Arcturus' efforts in developing novel self-amplifying mRNA vaccines in collaboration with CSL Seqirus, positioning the company for greater innovation in infectious disease vaccines.
Arcturus Therapeutics (Nasdaq: ARCT) announced a global partnership with CSL for developing self-amplifying mRNA vaccines, securing $200 million upfront and up to $4.3 billion in potential milestones. BARDA awarded $63.2 million for mRNA vaccine development targeting pandemic influenza. Recent data show the effectiveness of ARCT-032 in restoring chloride ion current in cystic fibrosis patients. For Q3 2022, Arcturus reported revenues of $13.4 million, a substantial increase from $2.4 million in Q3 2021, but a net loss of $35.3 million. Cash reserves stood at $237.7 million as of September 30, 2022.
Scholar Rock (NASDAQ: SRRK) appointed Dr. Jing L. Marantz as Chief Medical Officer, bringing over 20 years of experience in neurology, hematology/oncology, and rare diseases. Dr. Marantz, previously of Krystal Biotech, will oversee clinical development including the Phase 1 DRAGON trial for SRK-181 and Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy (SMA). CEO Jay Backstrom noted her expertise will enhance the company’s innovative approach to targeting TGFβ growth factors.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced its participation in two upcoming investor conferences. The Company will host a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on November 15, 2022, at 2:45 p.m. ET, and present at the 34th Annual Piper Sandler Healthcare Conference on November 29, 2022, at 11:30 a.m. ET. Arcturus focuses on developing mRNA medicines targeting infectious diseases and rare liver and respiratory conditions.
An agreement between Arcturus Therapeutics (NASDAQ: ARCT) and CSL Seqirus has been announced, positioning Arcturus for a potential financial boon. The collaboration includes an upfront payment of
FAQ
What is the current stock price of Arcturus Therapeutics Holdings (ARCT)?
What is the market cap of Arcturus Therapeutics Holdings (ARCT)?
What does Arcturus Therapeutics specialize in?
What are the core technologies of Arcturus Therapeutics?
What kind of diseases is Arcturus targeting with its therapies?
What recent collaborations has Arcturus entered into?
What is Kostaive®?
Who are Arcturus' major partners?
What is LUNAR-OTC?
How extensive is Arcturus' patent portfolio?
Where is Arcturus Therapeutics headquartered?
How can I get more information about Arcturus Therapeutics?
